Browsing Tag
Eli Lilly
51 posts
Novo Nordisk eyes FDA approval for high-dose 7.2mg Wegovy after STEP UP trial shows 21% weight loss
Novo Nordisk seeks U.S. approval for 7.2mg Wegovy after 21% average weight loss in trials. Can it outpace Eli Lilly’s Zepbound in the obesity drug race?
Novo Nordisk stock rises on Wegovy STEER data: Can semaglutide cement its lead over Eli Lilly?
Novo Nordisk shares gained after STEER study showed Wegovy cut heart risks by 57% over tirzepatide. Find out why semaglutide may lead the GLP-1 race.
Innovent Biologics secures FDA greenlight for first global Phase 3 trial of IBI363 in lung cancer
Innovent Biologics wins FDA approval for its first global Phase 3 trial of IBI363 in lung cancer, signaling a major milestone in immuno-oncology.
Can oral GLP-1 pills match injected options in efficacy and patient adherence? What’s next for Wegovy and Rybelsus
Can oral GLP-1 drugs like Wegovy and orforglipron match injectables in weight loss and adherence? Discover what’s next in chronic obesity treatment.
How oral obesity drugs are changing treatment access: A look at semaglutide, amycretin, and orforglipron
Oral GLP-1 drugs like semaglutide, amycretin, and orforglipron are redefining obesity care. Explore trial data, payer impact, and what’s ahead for access and scale.
Can dual agonist drugs like amycretin and tirzepatide replace bariatric surgery by 2030?
Can new obesity drugs like amycretin and tirzepatide replace bariatric surgery by 2030? Discover what clinical data and cost trends reveal about the future.
How are GLP-1 drugs like Wegovy and Zepbound reshaping obesity care beyond weight loss in 2025?
GLP-1 drugs like Wegovy and Zepbound are reshaping obesity care in 2025, with benefits extending to cardiovascular, liver, and kidney health. Learn more now.
Eli Lilly’s oral weight-loss pill shakes Novo Nordisk as investors brace for market shift
Novo Nordisk shares drop after Eli Lilly’s oral weight-loss pill shows promise. Analysts see a shifting obesity drug market. What this means for investors.
Scribe Therapeutics unveils ELXR technology breakthrough at Keystone Symposia 2025
Scribe Therapeutics has presented new data on its Epigenetic Long-Term X-Repressor (ELXR) technology at the 2025 Keystone Symposia…
Pfizer reports strong Q4 2024 earnings, reaffirms 2025 guidance amid cost-cutting strategy
Pfizer Inc. delivered strong fourth-quarter 2024 earnings, exceeding analyst expectations and demonstrating resilience in a challenging pharmaceutical market.…